about
Influence of immunoglobulin isotype on therapeutic antibody functionNeutrophils in Cancer: Two Sides of the Same CoinTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyIgE immunotherapy against cancerSimultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in disease.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Exploitation of the Polymeric Immunoglobulin Receptor for Antibody Targeting to Renal Cyst Lumens in Polycystic Kidney DiseaseEnhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) bindingA comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingEnhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors.Immunoglobulin A: magic bullet or Trojan horse?Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in PlantsHuman Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CAAntibody Isotypes for Tumor Immunotherapy.Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.
P2860
Q26772080-869E51E7-E899-45E1-8D1C-4323FF0EB101Q26773072-20BC8D69-63AE-4231-A2A5-97513D632EECQ26993238-75205725-1CC6-4A16-88BF-AC61666AACC6Q28081223-AF030C90-32E9-4180-80D5-EAFACAF89CD5Q33889191-2C1FEAFC-292B-4E0F-8002-89AF98B1E877Q33891585-88EB8E63-08BC-4FB3-8FD7-A6E5546EC9E7Q34000700-14622ECA-4453-4FC1-87E6-0CD80B462FEFQ34499286-8C142372-CC20-43F1-A161-C3EFB61A46D1Q35569901-9409901F-F111-4E14-88F6-D6214C321A1CQ35860685-309B6CF6-15E3-4E37-B43B-603ABB6F0F52Q36216363-43789E53-9D09-46FD-A2DD-30B81D6531AEQ37138274-ECB1A60E-117C-42C3-9C50-9D394B948983Q37138332-1E0C1E50-2FC3-4A46-901F-500599D1AFF1Q37593675-E0F1EF8C-AE53-496C-9B41-6139648B2E36Q38778020-DECFF45E-B630-4963-9B36-027DC7CFD0BCQ39027573-CEF09C7A-D035-491F-B247-512EA53591B1Q40011916-44932EED-BAF9-4F5E-A845-3B2D24F400DBQ41704272-2346C8F8-4773-48D4-BFE6-4FBA082429BCQ42557137-83F46A11-B24C-44D7-81CD-39CC21A687CAQ42660171-84FFC645-B636-4770-A6B2-8E36033B8FCAQ48223734-E46AE476-6FD8-46ED-8538-EB60714AC2ADQ52648924-EA31DFA8-4C76-4C05-B0E4-4F4692FB8B3BQ52731744-D7355D83-7933-42C8-A952-B9E33E63063CQ55439903-1E2E8EFF-CC9C-4D0B-9EE7-B6088D3C3AE0
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
IgA EGFR antibodies mediate tumour killing in vivo.
@en
IgA EGFR antibodies mediate tumour killing in vivo.
@nl
type
label
IgA EGFR antibodies mediate tumour killing in vivo.
@en
IgA EGFR antibodies mediate tumour killing in vivo.
@nl
prefLabel
IgA EGFR antibodies mediate tumour killing in vivo.
@en
IgA EGFR antibodies mediate tumour killing in vivo.
@nl
P2093
P2860
P356
P1476
IgA EGFR antibodies mediate tumour killing in vivo.
@en
P2093
Geert van Tetering
Jan G J van de Winkel
Jeanette H W Leusen
Johannes Hendrik Marco Jansen
Li Phing Liew
Louis Boon
Louise Royle
Maaike Nederend
Matthias Peipp
Michael Dechant
P2860
P304
P356
10.1002/EMMM.201201929
P577
2013-08-01T00:00:00Z